408 related articles for article (PubMed ID: 37141147)
1. Metabolomic profiling to identify early urinary biomarkers and metabolic pathway alterations in autosomal dominant polycystic kidney disease.
Houske EA; Glimm MG; Bergstrom AR; Slipher SK; Welhaven HD; Greenwood MC; Linse GM; June RK; Yu ASL; Wallace DP; Hahn AK
Am J Physiol Renal Physiol; 2023 Jun; 324(6):F590-F602. PubMed ID: 37141147
[TBL] [Abstract][Full Text] [Related]
2. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease.
Baliga MM; Klawitter J; Christians U; Hopp K; Chonchol M; Gitomer BY; Cadnapaphornchai MA; Klawitter J
Sci Rep; 2021 Mar; 11(1):6629. PubMed ID: 33758231
[TBL] [Abstract][Full Text] [Related]
3. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
Kistler AD; Serra AL; Siwy J; Poster D; Krauer F; Torres VE; Mrug M; Grantham JJ; Bae KT; Bost JE; Mullen W; Wüthrich RP; Mischak H; Chapman AB
PLoS One; 2013; 8(1):e53016. PubMed ID: 23326375
[TBL] [Abstract][Full Text] [Related]
4. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease.
Taylor SL; Ganti S; Bukanov NO; Chapman A; Fiehn O; Osier M; Kim K; Weiss RH
Am J Physiol Renal Physiol; 2010 Apr; 298(4):F909-22. PubMed ID: 20130118
[TBL] [Abstract][Full Text] [Related]
5. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
6. Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.
Sorić Hosman I; Cvitković Roić A; Fištrek Prlić M; Vuković Brinar I; Lamot L
Front Pediatr; 2023; 11():1274435. PubMed ID: 38027263
[TBL] [Abstract][Full Text] [Related]
7. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
[TBL] [Abstract][Full Text] [Related]
8. Matrix Metalloproteinase-7 in Urinary Extracellular Vesicles Identifies Rapid Disease Progression in Autosomal Dominant Polycystic Kidney Disease.
van Heugten MH; Blijdorp CJ; Arjune S; van Willigenburg H; Bezstarosti K; Demmers JAA; Musterd-Bhaggoe U; Meijer E; Gansevoort RT; Zietse R; Hayat S; Kramann R; Müller RU; Salih M; Hoorn EJ;
J Am Soc Nephrol; 2024 Mar; 35(3):321-334. PubMed ID: 38073039
[TBL] [Abstract][Full Text] [Related]
9. Alterations of Proximal Tubular Secretion in Autosomal Dominant Polycystic Kidney Disease.
Wang K; Zelnick LR; Chen Y; Hoofnagle AN; Watnick T; Seliger S; Kestenbaum B
Clin J Am Soc Nephrol; 2020 Jan; 15(1):80-88. PubMed ID: 31628117
[TBL] [Abstract][Full Text] [Related]
10. Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression.
Piazzon N; Bernet F; Guihard L; Leonhard WN; Urfer S; Firsov D; Chehade H; Vogt B; Piergiovanni S; Peters DJ; Bonny O; Constam DB
J Transl Med; 2015 Mar; 13():103. PubMed ID: 25888842
[TBL] [Abstract][Full Text] [Related]
11. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression.
Pejchinovski M; Siwy J; Metzger J; Dakna M; Mischak H; Klein J; Jankowski V; Bae KT; Chapman AB; Kistler AD
Nephrol Dial Transplant; 2017 Mar; 32(3):487-497. PubMed ID: 27382111
[TBL] [Abstract][Full Text] [Related]
12. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
Luan H; Liu LF; Tang Z; Zhang M; Chua KK; Song JX; Mok VC; Li M; Cai Z
Sci Rep; 2015 Sep; 5():13888. PubMed ID: 26365159
[TBL] [Abstract][Full Text] [Related]
14. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.
Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W
Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385
[TBL] [Abstract][Full Text] [Related]
16. Global microRNA profiling in human urinary exosomes reveals novel disease biomarkers and cellular pathways for autosomal dominant polycystic kidney disease.
Magayr TA; Song X; Streets AJ; Vergoz L; Chang L; Valluru MK; Yap HL; Lannoy M; Haghighi A; Simms RJ; Tam FWK; Pei Y; Ong ACM
Kidney Int; 2020 Aug; 98(2):420-435. PubMed ID: 32622528
[TBL] [Abstract][Full Text] [Related]
17. Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: A Biomarker of Disease Progression and Therapeutic Efficacy.
Alam A; Dahl NK; Lipschutz JH; Rossetti S; Smith P; Sapir D; Weinstein J; McFarlane P; Bichet DG
Am J Kidney Dis; 2015 Oct; 66(4):564-76. PubMed ID: 25960302
[TBL] [Abstract][Full Text] [Related]
18. Urinary MicroRNAs, Possible Biomarkers for Early Detection of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).
Ghasemi Y; Mardomi A; Alizadeh E; Khosroshahi HT
Iran J Kidney Dis; 2023 Mar; 1(2):73-78. PubMed ID: 37060340
[TBL] [Abstract][Full Text] [Related]
19. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
20. Clinical and laboratory markers of autosomal dominant polycystic kidney disease (ADPKD) progression: an overview.
Corradi V; Gastaldon F; Virzì GM; Caprara C; Martino F; Ronco C
Minerva Med; 2015 Feb; 106(1):53-64. PubMed ID: 25300895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
